Evidence map›Paper›PMID 41557073›Full record

ArticleBreast cancer research and treatment2026

Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy.

Rebecca Pedersini, Laura Moretti, Marta Laganà, Greta Schivardi, Valentin Baluta, Manuel Zamparini, Eleonora Conforti, Marco Ravanelli, Caterina Brentegani, Vito Amoroso and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rebecca Pedersini *Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Laura Moretti *Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Marta LaganàDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy. marta.lagana@unibs.it.
Greta SchivardiDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Valentin BalutaDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Manuel ZampariniDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Eleonora ConfortiDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Radiology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
Marco RavanelliDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Radiology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
Caterina BrenteganiDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Vito AmorosoDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Salvatore GrisantiDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Chiara BuizzaDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Giulia ScartabellatiDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Michela BazzoliDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Giuseppe IppolitoDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Federica PellicioliDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Davide FarinaDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Radiology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
Alfredo Berruti *Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.
Deborah Cosentini *Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInvestigate skeletal morbidity (SM) in metastatic breast cancer (MBC) patients undergoing CDK4/6 inhibitors (CDK4/6is) and endocrine therapy (ET).

methodsIn this retrospective study we evaluated skeletal morbidity - defined as the occurrence of skeletal-related events (SREs) in metastatic bone and fragility fractures in non-metastatic bone - in 214 MBC patients who had received ET and CDK4/6is. As secondary aim, we compared VF progression, defined as a new fracture or worsening of a pre-existing fracture at spine CT scan, between 121 patients receiving ET alone (cohort A) and 121 patients on ET plus CDK4/6is (cohort B), balanced using propensity score.

resultsAmong the 147 patients (68.7%) with bone metastases, 59 (40.1%) experienced SREs including non-vertebral pathologic fractures (17 patients, 11.6%), pathologic VF progression (21 patients, 14.3%), spinal cord compression (3 patients, 2.0%), radiation to bone (18 patients, 12.2%). Considering the non-metastatic bone, 3 out of 214 patients (1.4%) experienced new non-vertebral fragility fractures, and 26 patients (12.2%) had fragility VF progression. In the comparative study, pathologic VF progression in metastatic bone was 38.3% in cohort A and 29.1% in cohort B (p = 0.093). The corresponding fragility VF progression rate in non-metastatic bone was 22.3% and 12.4% (p = 0.031).

conclusionsA considerable proportion of women with MBC treated with CDK4/6is + ET experience SM on both metastatic and non-metastatic bone. Patients treated with CDK4/6is + ET had lower SM than those on ET alone.

Indexed as

Antineoplastic Agents, HormonalBone NeoplasmsBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Fractures, BoneProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMiddle AgedNeoplasm MetastasisRetrospective StudiesAntineoplastic Agents, HormonalCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsBone fragilityCDK 4/6 inhibitorsEndocrine therapyFracture riskSREs

Identifiers

PMID41557073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.